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Summary
Background/Aims Recent studies documented that sensitization and exposure to cockroach
allergens significantly increase children’s asthma morbidity as well as severity, especially
among inner city children. TNF-a has been postulated to be a critical mediator directly
contributing to the bronchopulmonary inflammation and airway hyper-responsiveness in
asthma. This study investigated whether an anti-TNF-a antibody would inhibit pulmonary
inflammation and methacholine (Mch) hyper-responsiveness in a mouse model of asthma
induced by a house dust extract containing both endotoxin and cockroach allergens.
Methods A house dust sample was extracted with phosphate-buffered saline and then used for
immunization and two additional pulmonary challenges of BALB/c mice. Mice were treated
with an intravenous injection of anti-TNF-a antibody or control antibody 1 h before each
pulmonary challenge.
Results In a kinetic study, TNF-a levels within the bronchoalveolar lavage (BAL) fluid
increased quickly peaking at 2 h while BAL levels of IL-4, IL-5, and IL-13 peaked at later
time-points. Mch hyper-responsiveness was measured 24 h after the last challenge, and mice
were killed 24 h later. TNF inhibition resulted in an augmentation of these Th2 cytokines.
However, the allergic pulmonary inflammation was significantly reduced by anti-TNF-a
antibody treatment as demonstrated by a substantial reduction in the number of BAL
eosinophils, lymphocytes, macrophages, and neutrophils compared with rat IgG-treated mice.
Mch hyper-responsiveness was also significantly reduced in anti-TNF-a antibody-treated
mice and the pulmonary histology was also significantly improved. Inhibition of TNF
significantly reduced eotaxin levels within the lung, suggesting a potential mechanism for the
beneficial effects.These data indicate that anti-TNF-a antibody can reduce the inflammation
and pathophysiology of asthma in a murine model of asthma induced by a house dust extract.
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Introduction
Asthma is a complicated chronic inflammatory disease of
the airways characterized by reversible airway obstruc-
tion, inflammatory mediator production, and airways
hyper- responsiveness (AHR) [1]. Following exposure to
allergens, numerous inflammatory cells and structural
cells are activated such as macrophages, eosinophils,
lymphocytes, and epithelial cells [1]. Upon activation,
several inflammatory changes in the airways are triggered
with the subsequent release of a wide variety of immuno-
modulator molecules into the airway [2]. Asthma is
known as a T helper type 2 (Th2) disease with a specific
cytokine profile including IL-4, IL-5, and IL-13 [3]. How-
ever, recent publications suggested that other cytokines
categorized as T helper type 1 are also associated with
asthmatic pulmonary inflammation in animals as well as
in humans [4, 5]. TNF-a, a potent pro-inflammatory
mediator, plays various roles in the immunoregulation of
asthma such as alteration of bronchial hyper-responsive-
ness [6], airway infiltration of neutrophils [7], activation
of airway smooth muscle [8], activation of myofibroblasts
[9], and changes in vascular permeability [10] including
up-regulation of adhesion molecules such as E-selection,
vascular cell adhesion molecule-1 and intercellular adhe-
sion molecule-1 [11, 12]. In addition, TNF-a plays an
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important role in recruitment and activation of airway
eosinophils [7, 13]. It has been documented that TNF-a
expression within the airways of asthmatics is signifi-
cantly increased in human subjects [14]. TNF-a is pro-
duced by various cell types in response to allergic
pulmonary inflammation including mast cells, macro-
phages, neutrophils, eosinophils, and epithelial cells [2, 6].
In previous studies, we have developed a murine model
of allergic asthma which shows methacholine (Mch)
hyper-responsiveness, bronchopulmonary recruitment of
inflammatory cells, and pulmonary expression of chemo-
kines following house dust extract immunization and
challenge [15, 16]. This murine model was specifically
developed following a landmark study that documented a
strong correlation between sensitization to cockroach
allergens and symptoms among asthmatic children in
inner cities [17]. The model is based upon the use of house
dust extracts containing high levels of cockroach aller-
gens as well as endotoxin. This model of asthma-like
pulmonary inflammation demonstrates recruitment of
neutrophils, lymphocytes, and eosinophils into the lung,
as well as Mch hyper-reactivity, and production of typical
pro- inflammatory cytokines implicated in the pathogen-
esis of asthma. This unique model may be exploited
further to examine therapeutic modalities to treat asthma.
In the present study, we sought to determine whether a
treatment option for acute asthma, such as neutralization
of TNF-a would prevent an asthmatic response using this
model. To examine this, animals were treated with the
anti-TNF-a antibody before the onset of an asthmatic
response, to investigate the role of TNF-a in pulmonary




Female BALB/c mice (18–20 g) were purchased from
Harlan Sprague Dawley Inc. (Indianapolis, IN, USA) and
maintained under standard laboratory conditions. The
mice were housed in a temperature-controlled room with
a 12-h dark/light cycle and allowed food and water ad
libitum. All experiments described below were performed
in accordance with the National Institutes of Health
guidelines, and approved by the University of Michigan
Animal Use Committee.
Sensitization and airway challenge
The household dust used for all sensitizations and airway
challenges was collected from a house in Detroit, MI as
previously reported [16]. Briefly, a total of 4.3 g of dust
was collected and resuspended with 30 mL of sterile
phosphate-buffered saline (PBS) to allow aqueous extrac-
tion. The collected supernatant was assayed for six differ-
ent indoor allergens and three different outdoor allergens
by ELISA. Our house dust extract contained very high
concentrations of cockroach allergens (378 U/mL of Bla g
1 and 6249 ng/mL of Bla g 2), and contained extremely
low levels of four indoor allergens (dust mite Der p 1 and
Der f 1, dog Can f 1 and cat Fel d 1) and three outdoor
allergens (ragweed, mould, and grass). In addition to these
allergens, our house dust extract contains 270 pg/mL of
endotoxin. The house dust extract was diluted 1 : 10 for all
experiments.
We used our previously described model of asthma [16]
to induce the response. Mice were sensitized with an
intraperitoneal (100 mL) injection of house dust extract
mixed 1 : 1 with an adjuvant (TiterMax Gold, CytRx,
Norcross, GA, USA) on day 0. On days 14 and 21, mice
were given pulmonary challenges of 50 mL of house dust
extract while under isoflurane anaesthesia (Aerranes,
Baxter, Deerfield, IL, USA). Hyper-responsiveness to Mch
was measured on day 22, 24 h after the last pulmonary
challenge. Mice were sacrificed 48 h after the last chal-
lenge (day 23). For one set of experiments, groups of mice
were sacrificed at multiple time-points after the last
pulmonary challenge to closely define the production of
inflammatory mediators within the lung.
Anti-TNF-a antibody treatment
Neutralizing rat anti-mouse TNF-a monoclonal antibody
(mAb) was used to block TNF-a bioactivity in HDE-
sensitized and challenged BALB/c mice. On day 14 and
21, the immunized mice were treated with 10 mg rat anti-
murine TNF-a mAb (Biosource International Inc., Camar-
illo, CA, USA) or 10 mg rat IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) by intravenous (iv)
injection 1 h before the pulmonary challenge. This dose of
anti-TNF-a antibody has been used successfully to neu-
tralize TNF activity in vivo [18] although it is possible that
higher doses would have been even more efficacious.
Measurement of methacholine hyper-responsiveness
Whole body plethysmography (Buxco, Troy, NY, USA) was
used to measure airway hyper-responsiveness (AHR) in
response to increasing doses of aerosolized acetyl b-
methylcholine (Sigma, St Louis, MO, USA) in unrestrained
and conscious mice as previously reported [16]. Changes
in early expiration because of bronchoconstriction will
alter the waveform of the box pressure-time and can be
quantified. These quantified alterations are expressed as
enhanced pause (Penh) as a main indicator of airway
obstruction. Penh is strongly correlated with the airway
resistance of the animal [19]. Either aerosolized PBS or
Mch in increasing doses (6, 12, 25, and 50 mg/mL) was
nebulized through the inlet of the main chamber for
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2 min, and the response to each dose was subsequently
measured for 5 min. The average Penh for 5 min was used
to compare the results among experimental groups.
Peripheral blood analysis
For blood characterization, 20 mL of EDTA (Sigma) anti-
coagulated blood was collected from the tail 48 h after the
second airway challenge from mice anaesthetized with
ketamine and xylazine solutions (87 mg/g Ketamine plus
13 mg/g Xylazine, Ketasets; Fort Dodge Laboratories Inc.,
Fort Dodge, IA, USA. Rompuns; Bayer Corporeation,
Shawnee Mission, KS, USA). A Hemavet Mascot Multi-
species Hematology System Counter 1500R (CDC Tech-
nologies Inc., Oxford, CT, USA) was used for a complete
blood count [20]. Blood was also collected from the retro-
orbital venous plexus into tubes containing 50 U of
porcine derived heparin (Elkins-Sinn Inc., Cherry Hill,
NJ, USA) before sacrifice. Plasma was collected by cen-
trifugation (600 g, 5 min) and stored at  20 1C for later
chemokine and cytokine analyses.
Bronchoalveolar lavage fluid
After blood collection, mice were euthanized by cervical
dislocation. For the BAL, the trachea was exposed and
intubated with a polyethylene catheter. BAL fluid was
collected by washing with two separate aliquots of 1 mL of
Hanks’ Balanced Salt Solution (HBSS, Gibco-BRL, Grand
Island, NY, USA) through the trachea. The first wash was
centrifuged and the BAL supernatant stored for cytokine
and chemokine analysis. The second wash was centri-
fuged, and the cell pellet from the first wash was pooled
with the cell pellet from the second. A total cell count was
obtained by using a Coulter counter model ZF (Coulter
Electronics Inc., Hialeah, FL, USA). For differential count-
ing, cells were prepared in a cytospin apparatus. Prepared
cytospin slides were stained with Diff-Quick (Baxter,
Detroit, MI, USA) and cell differentials were performed
after counting 300 cells.
Histopathology
Immediately after collecting the BAL, the left lung and
trachea from each mouse was removed, fixed in 10%
buffered formalin, and processed for routine histology in
paraffin. Tissue sections were stained with haematoxylin/
eosin and then examined under light microscopy by a
board-certified pathologist (DGR). Digital images were
taken of each of the lung from each animal and the entire
histologic section on the glass slide was selected and areas
quantified using the NIH ImageJ software. The outline of
each region of interest was traced and areas in square
pixels are calculated using the measure feature. Areas of
inflammation were calculated by measuring the peribron-
chial and perivascular areas occupied by inflammatory
cells and subtracting the area of the inner null space. For
each section, the sum of these areas of inflammation is
expressed as the percentage of the total area of the section.
Preparation of lung homogenates
After the BAL fluid was collected, the right lung was
removed and immediately placed in 3 mL of ice-cold
homogenization buffer (0.05% Triton X-100 (Sigma) in
PBS). Three, 10-s rounds of homogenization and sonica-
tion were followed by centrifugation (15 000 g for
15 min at 4 1C). This supernatant was used directly in the
eotaxin ELISA. For the myeloperoxidase assay, the super-
natant was mixed 1 : 1 with MPO assay buffer and added
to 96-well plate (20 mL). Assay buffer (200 mL) containing
100 mM potassium phosphate, 0.834 mL o-dianisidine HCl
(10 mg/mL, Sigma) and 0.083 mL 0.3% H2O2 in 50 mL
deionized water was added immediately before reading.
The reaction was assayed in a Biotek microplate reader
(Bio-Tek Instruments, Inc., Winoski, VT, USA) every 10 s at
465 nm. The data were expressed as the slope of change in
optical density over 100 s. It should be noted that our
myeloperoxidase assay of lung homogenates measured
peroxidase from neutrophils and eosinophils [21].
Cytokine and chemokine analysis
All chemokine and cytokine measurements were per-
formed simultaneously to reduce errors because of inter-
assay variation. TNF-a and eotaxin were measured by
ELISA using matched antibody pairs (R&D Systems Inc.,
Minneapolis, MN, USA) as previously described [22]. For
the lung homogenate eotaxin ELISA, the standard was
diluted in homogenate fluid from normal lungs in order to
keep a similar protein background in both samples and
standard. IL-4, IL-5, and IL-13 were measured by a multi-
plex, microarray immunoassay developed in our labora-
tory [23]. These cytokines were measured in this format so
that we would be able to measure all three of the cytokines
with the small amount of remaining sample.
Statistical analyses
Mean standard error of the mean was used for summary
statistics in all figures. Differences between all treatment
groups were compared by ANOVA. A Tukey’s test for pair-wise
comparisons was performed when the overall F-value was
statistically significant (Po 0.05).
Results
Kinetics of bronchoalveolar lavage TNF-a after immunization
and challenge
To investigate the role of TNF-a in this murine model of
asthma, BALB/c mice were immunized and intratracheally
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challenged with a house dust extract containing high levels
of cockroach allergens as well as endotoxin. Groups of mice
were immunized on day 0 and received pulmonary chal-
lenges on day 14 and 21. After the last challenge (day 21),
mice were sacrificed at time intervals from 2 to 60h and
BAL fluid was collected. A group of mice were sacrificed at
0 h, that is on day 21 but before the second pulmonary
challenge. The concentration of TNF-a in lung lavage fluid
was below detection limits immediately before the second
pulmonary challenge. On day 21, 2 h after the last intra-
tracheal challenge, TNF levels in the lavage peaked and
then declined (Fig. 1). Pulmonary expression of TNF-a
declined dramatically within 24h of the last challenge.
These results are similar to other reports where TNF peaks
rapidly in the BAL fluid after pulmonary challenge [24] and
provide a strong rationale for targeting TNF-a.
Kinetics of bronchoalveolar lavage interleukin-4, -5, and
-13 after immunization and challenge
As the Th2 cytokines IL-4, IL-5, and IL-13 have been
implicated in the pathogenesis of asthma [25],we mea-
sured their levels in the BAL fluid after the last pulmonary
challenge (Fig. 2). Similar to TNF, none of these cytokines
were detectable at time 0, i.e. immediately before the last
pulmonary challenge. Each of these cytokines became
elevated, although the kinetics were slightly delayed
relative to the production of TNF observed in Fig. 1. The
local levels of these cytokines also persisted longer, with
detectable levels still present beyond 24 h after the last
pulmonary challenge.
Anti-TNF-a antibody increases bronchoalveolar lavage
levels of T helper type 2 cytokines
BAL samples from the 48-h time-point were examined for
Th2 cytokine levels to determine if the levels would be
modulated by anti-TNF-a antibody therapy. Surprisingly,
each of the Th2 cytokines was significantly elevated when
TNF was inhibited (Fig. 3). We next examined whether the
pulmonary inflammation would be altered by blockade of
TNF.
Anti-TNF-a reduces antibody pulmonary recruitment of
inflammatory cells
TNF was inhibited by the iv injection of a rat anti-mouse
TNF-a antibody 1 h before both of the intratracheal
challenges and mice were sacrificed 48 h after the last
















Fig. 1. Kinetics of TNF-a expression in mouse lung lavage from house
dust extract sensitized and challenged BALB/c mice. Groups of mice were
sacrificed and BAL was collected at the indicated time-points after the
last challenge. TNF-a concentrations were determined using matched
antibody pairs via ELISA. Values represent mean SEM with n = 4 for
each group.




















































Fig. 2. Kinetics of IL-4, IL-5, and IL-13 expression in mouse lung lavage
from house dust extract sensitized and challenged BALB/c mice. Each
group of mice was sacrificed and BAL was collected after the last
challenge at the indicated time-points. The concentrations of each
cytokine were measured by a multiplex, microarray immunoassay
developed in our laboratory. Values represent meanSEM with n = 4
for each group.
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challenge. As shown in Fig. 4, the numbers of inflamma-
tory cells in BAL including total leucocytes, eosinophils,
lymphocytes, and macrophages in anti-TNF-a antibody-
treated mice were significantly lower than those in the
control rat IgG-treated mice. Additionally, the number of
neutrophils recovered from the BAL was significantly
reduced (Fig. 5). The effect of antibody treatment on the
pulmonary recruitment of neutrophils in this model was
further evaluated by measurement of pulmonary myelo-
peroxidase activity (Fig. 5). Using the myeloperoxidase
assay, the neutrophil activity within the lung tissue was
significantly decreased in anti-TNF-a antibody-treated
mice (Po 0.01) compared with the control, rat IgG-
treated mice. Even though it is important to distinguish
between eosinophils and neutrophils in the asthmatic
inflammatory reaction [21], our myeloperoxidase assay
of lung homogenates measured peroxidase from neutro-
phils and eosinophils.
Inflammatory cell recruitment into the lungs of anti-
TNF-a antibody-treated mice was further investigated by
histopathological studies (Figs 6 and 7). Mice were im-
munized and challenged according to the standard proto-
col, and separate groups treated with control antibody or
anti-TNF-a antibody. Lungs were harvested and processed
for histology 48 h after the last pulmonary challenge and
BAL collection. Control antibody-treated mice (Fig. 6a)
had a significant influx of inflammatory cells that in-
cluded lymphocytes and eosinophils. These cells were
located in both the peribronchial and perivascular spaces.
The infiltration of inflammatory cells was significantly
reduced by anti-TNF-a antibody treatment and was, in
fact, nearly similar to normal mouse histology (Fig. 6b). It
was difficult to discern any significant inflammation in
some of the anti-TNF-a antibody-treated mice. Pulmon-
ary infiltration of inflammatory cells was further con-
firmed by computer-aided morphometry of the histologic
sections. The total area of occupied by inflammation in
the anti-TNF-a antibody-treated mice was significantly
lower than the rat IgG-treated mice (Fig. 7).
We then ascertained whether the numbers of circulating
inflammatory cells were affected by iv administration of
anti-TNF-a antibody. Immunized and challenged mice
were sacrificed 48 h after the last intratracheal challenge
and peripheral blood was harvested for complete blood
counting. Interestingly, the total number of peripheral
white blood cells, lymphocytes, and monocytes in the
anti-TNF-a antibody-treated mice were higher than in mice
treated with rat IgG (data not shown), indicating that the
anti-TNF-a antibody treatment did not have a non-specific
toxic effect. A similar result has been observed in patients
with rheumatoid arthritis who are treated with antibodies
to TNF because they also have a leucocytosis [26].
Anti-TNF-a antibody improves methacholine hyper-
responsiveness
An increase in AHR to Mch challenge has been considered
a diagnostic sign in models of allergic asthma [27]. To
confirm the beneficial effects of the anti-TNF-a antibody
treatment, mice were evaluated by measuring Penh via
whole body plethysmography. Mch hyper-responsiveness
was measured 24 h after the last pulmonary challenge. As
shown in Fig. 8, bronchopulmonary hyper-responsiveness
in response to increasing doses of Mch in the anti-TNF-a
antibody-treated and rat IgG-treated mice increased in a
dose-dependent manner. AHR in anti-TNF-a-treated mice
was significantly reduced when compared with control
IgG-treated mice (P = 0.03 and 0.02 at 25 mg/mL and
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Fig. 3. Increased expression of IL-4, IL-5, and IL-13 in BAL after anti-
TNF-a Ab treatment. Mice were treated with an intravenous (iv) injection
of anti-TNF-a Ab or control rat IgG and BAL collected at 48 h after the
last challenge. For each of these Th2 cytokines, inhibition of TNF
increased the BAL concentrations. Values represent mean SEM with
n = 6–8 for each group. wBelow detectable level.
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Effects of anti-TNF-a antibody treatment on pulmonary
expression of chemokines
We had previously demonstrated that inhibition of eotax-
in would reduce pulmonary inflammation in this murine
model of asthma [16]. Several investigators have pub-
lished that TNF will induce the expression of eotaxin in
cells present in normal lungs such as airway smooth
muscle cells [28] or bronchial epithelial cells [29, 30]. If
the anti-TNF-a antibody decreased eotaxin levels it would
suggest a potential mechanism of how TNF reduced the
pulmonary inflammation. For these studies, we examined
the eotaxin levels within the blood, BAL and lung homo-
genates 48 h after the last pulmonary challenge. The BAL
levels of eotaxin were below detection limits and there
was no difference in the blood eotaxin levels between
anti-TNF-a antibody and control rat IgG mice. However,
blockade of TNF did result in a significant reduction in the
levels of eotaxin in the lung homogenates (Fig. 9).
Discussion
Asthma is one of the commonest illnesses in western
countries and affects 8–10% of children and 3–5% of the
adult population [31]. In the United States, approximately
17 million Americans suffer from asthma [32]. Among
them, 4.8 million are children under the age of 18 [33].
The morbidity and mortality because of asthma have
increased 75% from 1980 to 1994 in the United States
[32] and the reasons for this recent increase have not been
fully identified. Increased levels of indoor allergens in-
cluding dust mite, cockroach, and pet dander represent
some of possible reasons [34, 35]. Recent published
studies have demonstrated that sensitization to cockroach
allergens is strongly correlated with the increased asthma
morbidity for both adults and children, especially children
living in the inner cities of the United States [17, 36]. Thus,
it is of great interest to develop experimental murine
models that demonstrate the principal aspects of asthma
by using house dust containing high levels of cockroach
allergens.
Pulmonary inflammation and structural changes in the
airways induce AHR via the expression of inflammatory
mediators including cytokines and chemokines (reviewed
in [2]). These inflammatory mediators induce remodelling
of asthmatic airways through the modification of the
smooth muscle contractility, influx of inflammatory cells,
vascular permeability, and mucus secretion [37–39]. Un-
derstanding the role of the cytokines and chemokines that
modulate the pathophysiology of asthma is essential to
the development of new interventions for the treatment of
asthma.
TNF-a, a multifunctional pro-inflammatory cytokine,
has been postulated to play an important role in the
pathogenesis of asthma [9, 40, 41]. Various in vivo studies
have shown involvement of TNF-a in asthma by alteration
of the contractile properties of the airway smooth muscle
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Fig. 4. Antibody treatment decreases BAL inflammatory cell infiltration. Mice were treated with anti-TNF-a antibody (10 mg per mouse) or rat IgG 1 h
before each pulmonary challenge and BAL cells determined 48 h after the last intratracheal challenge. Values represent mean SEM with n = 8 for each
group. Po 0.05, Po 0.01, or Po 0.001 when compared with rat IgG-treated mice.
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overexpressed in blood and BAL of asthma patients [14,
43]. TNF has been found by immunostaining to be present
in the bronchial biopsies from asthmatic patients [44, 45].
This expression of pro-inflammatory cytokines is aug-
mented by environmental mediators such as endotoxin
that are frequently present in house dust [46]. Further,
alveolar macrophages from wheezy infants show in-
creased spontaneous release of TNF [47].
We previously reported a murine model of asthma-like
bronchopulmonary inflammation induced by a house dust
extract that contained high levels of cockroach allergens
and moderate levels of lipopolysaccharide [15, 16]. This
murine model of asthma simulates many features of
human asthma including exacerbation of AHR, pulmon-
ary infiltration of inflammatory cells, and increased
recruitment of inflammatory cells and chemokines in
BAL.
In this study, we investigated the effects of anti-TNF-a
antibody treatment on the features demonstrated in a
murine model of asthma in an effort to expand the current
understanding of the mechanism of AHR and pulmonary
inflammation. The role of TNF-a in asthma remains
controversial with conflicting results in the literature. In
an ovalbumin (OVA) model of murine asthma, Rudmann
et al. [48]found that TNF receptor knockout mice (lacking
both TNF receptors) had pulmonary inflammation com-
parable to wild-type mice. However, Broide et al.
[49]found decreased pulmonary inflammation in the TNF
receptor knockout mice also while using an OVA model.
Blockade of TNF activity has been performed using either
antibodies or TNF soluble receptors. In the OVA model,
some groups have shown that blocking TNF does not alter
cellular recruitment [48, 50] while others have demon-
strated a reduction in the pulmonary recruitment of
inflammatory cells [51–53]. In a model of occupational
asthma, blockade of TNF had a beneficial effect [54]. Our
data shows a strong protective effect when TNF is inhib-
ited in our model of murine asthma. A strength of the





































Fig. 5. Anti-TNF-a antibody treatment decreases the number of neutro-
phils in lung lavage and pulmonary myeloperoxidase activity. After the
BAL fluid was collected, the right lung was removed and immediately
processed for the assay. Inhibition of TNF decreased both the number of
recruited neutrophils as well as the myeloperoxidase activity of the lung.
Values represent meanSEM with n = 8 for each group. Po 0.01
when compared with rat IgG-treated mice.
Fig. 6. Histology of lung tissue in anti-TNF-a antibody and rat IgG-
treated mouse after immunized and challenged with house dust extract.
Lungs were harvested 48 h after the last pulmonary challenge and after
bronchoalveolar lavage (BAL) fluid was harvested. (a) Representative
histology from a rat IgG-treated mouse with a marked peribronchial and
perivascular infiltration of eosinophils and lymphocytes. (b) Representa-
tive histology from an anti-TNF-a antibody-treated mouse with essen-
tially normal histology. Both pictures same magnification.
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that blocking TNF will improve outcome. As the model is
based on house dust actually obtained from the homes of
children with asthma, the results discussed in this report
may be more indicative of the role of TNF in human
disease.
In addition to measuring TNF, we also measured the Th2
cytokines IL-4, IL-5, and IL-13. In the kinetics studies, the
cytokines peaked at later time-point compared to TNF
with IL-4 peaking at 4 h, IL-5 at 8 h, and IL-13 between 12
and 24 h. These chemokines have been reported to be
critical in the host response to allergic type inflammation
[25]. In what might appear to be a paradoxical response,
inhibition of TNF resulted in augmentation of these Th2
cytokines. However, as the data indicates, blocking TNF
significantly reduced the inflammatory response. The
increase in the Th2 cytokines may represent a compensa-
tory response in attempt to increase the pulmonary
inflammation. This has been observed with other cyto-
kines, where an increase in local concentrations is ob-
served in attempt to attain what the host perceives to be
the appropriate inflammatory response [55, 56]. In other
words, the Th2 cytokines increase in attempt to increase
the level of pulmonary inflammation, even though this
was not successful. As an example, IL-4 has been shown to
increase mast cell secretion of histamine and leucotrienes
[57] so IL-4 levels may be increased to try and augment
the recruitment of inflammatory cells.
The mechanism of the inhibition of TNF was also
explored in this study by examining the regulation of
eotaxin. Several investigators have documented the im-
portance of the double cysteine (CC) chemokine eotaxin in
the pathogenesis of asthma. Previous work has correlated
the levels of eotaxin with pulmonary eosinophils in
animal models [1, 58, 59]. The correlation of eotaxin with
pulmonary inflammation has also been observed in hu-
mans [60]. A strong link exists between TNF and eotaxin
because several investigators have demonstrated that TNF
will increase eotaxin [61, 62]. There are several types of
cells present in normal lung that may be stimulated with
TNF to produce eotaxin. Included in this list are fibro-
blasts [63–65], airway smooth muscle cells [66], mesothe-
lial cells [67], and airway epithelial cells [29, 30]. In one
study, TNF was able to induce eotaxin production in
fibroblasts, endothelial cells and epithelial cells [68].
Additionally, several studies have shown that numerous
inflammatory mediators will synergize with TNF to induce
eotaxin [30, 63, 68]. These previous studies provide a
potential mechanism of how the blockade of TNF will
reduce asthma-like pulmonary inflammation.
Blockade of TNF has already been used to treat human
diseases of chronic inflammation. The synthesis and
activity of TNF-a can be blocked by various ways includ-
ing monoclonal antibodies to TNF-a-soluble TNF recep-
tors, and TNF-a converting enzyme inhibitor [46, 69, 70].

















Fig. 8. Airway hyper-responsiveness (AHR) reduced in anti-TNF-a Ab-
treated mice. Penh values were obtained from mice 24 h after the last
challenge in response to nebulized methacholine (Mch) via whole body
plethysmography. The data are expressed as the meanSEM of Penh



















Fig. 9. Reduced levels of eotaxin in the lung of BALB/c mice treated with
anti-TNF-a antibody. Chemokine levels were determined by ELISA in the
blood and in the lung homogenate harvested at 48 h after the last
intratracheal challenge. Values represent mean  standard error of the
mean (SEM) with n = 6–8 for each group. Po 0.01 compared with rat
IgG-treated mice.























Fig. 7. Anti-TNF-a antibody treatment reduced pulmonary inflamma-
tion. Digital images were taken from lungs harvested as described in Fig.
6, the entire histologic section on the glass slide was selected and areas
are quantified using the NIH ImageJ software. The area of inflammation
was calculated by measuring the peribronchial and perivascular areas
occupied by inflammatory cells and subtracting the area of the inner null
space. The data are expressed as the percentage of the total lung area
occupied by inflammation. Po 0.01 when compared with rat IgG-
treated mice.
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Currently an anti-TNF-a blocking antibody is being used
to treat chronic inflammatory diseases including Crohn’s
disease, psoriatic arthritis, and rheumatoid arthritis [71].
The studies using TNF inhibitors for the treatment of
rheumatoid arthritis extend back several years and the
clinical results have been impressive [72]. These dramatic
results with TNF inhibitors in human patients provide a
strong rationale for their use in other chronic diseases
such as asthma.
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